Proteasome inhibitors containing Boron to be used after Primary Therapy of cancer

摘要

p compounds containing Boron, Proteasome Inhibitors, to be used in at least four Treatment Cycles of 28 days after Primary Therapy of cancer with a inhihidor Proteasome or immunomodulatory Drug, or both, followed by autologous stem cell transplantation or for pr Evenir progression or recurrence. / p